PRQR: ProQR Therapeutics N.V Company Profile & Statistics

About

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.

Info & Links

CEO

Daniel de Boer

Headquarters

ZERNIKEDREEF 9
LEIDEN, P7 2333 CK, NETHERLANDS

Auditor

KPMG Accountants N.V.

Share holders

Employees

156

ProQR Therapeutics N.V Statistics

Valuation Measures

Market Capitalization²

216.45M

Enterprise Value

123.11M

Enterprise Value/EBITDA(ttm)

-4.75

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

11.93

Price to Book(mrq)

8.41

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-134.31%

Profit Margin(ttm)

-148.19%

Return on Equity(ttm)

-71.58%

Return on Invested Capital(ttm)

-74.61%

Return on Assets(ttm)

-19.70%

Income Statement

Revenue(ttm)

19.39M

Revenue Per Share(ttm)

Gross Profit(ttm)

19.39M

EBITDA(ttm)³

-25.90M

Net Income Available to Common(ttm)

-26.04M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

0.24

52-Week Change

37.31%

S&P 500 52-Week Change

26.84%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

74.82M

% Held by Insiders

8.40%

% Held by Institutions

32.65%

Balance Sheet

Total Cash(mrq)

98.31M

Total Cash Per Share(mrq)

Total Debt(mrq)

4.96M

Total Debt/Equity(mrq)

18.05%

Current Ratio(mrq)

2.33%

Quick Ratio(mrq)

2.33%

Book Value Per Share(mrq)

0.33

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.36

Free Cash Flow(ytd)

-31.15M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PRQR

ProQR Therapeutics N.V

ProQR Therapeutics N.V Profile